Zhengye Biotechnology Holding (ZYBT) Current Leases (2025)

Zhengye Biotechnology Holding (ZYBT) posted quarterly Current Leases of $14945.2 for Q4 2025.

Zhengye Biotechnology Holding (ZYBT) Current Leases (2025) Analysis & Trends

Zhengye Biotechnology Holding (ZYBT) has reported Current Leases for 1 consecutive years, with $14945.2 the latest figure, recorded in Q4 2025.

  • Quarterly Current Leases changed N/A year-over-year to $14945.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14945.2 (changed N/A YoY) and the FY2025 annual result came in at $15000.0, changed N/A from the prior year.
  • Current Leases held at $14945.2 in Q4 2025 per ZYBT's latest filing.
  • Over the last five years, Current Leases for ZYBT reached as high as $14945.2 in Q4 2025 and fell as low as $14945.2 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Zhengye Biotechnology Holding 85.23 Mn 85.93 Mn - 14,945.22

Historic Data

Download Data
DateValue
Dec 31, 2025 14,945.22